Abstract
ABSTRACT Cilnidipine is an antihypertensive drug with low solubility and poor bioavailability. This study aimed to formulate and optimise nanoparticles to improve the solubility, drug release and bioavailability of cilnidipine. The cilnidipine nanoparticles were prepared by the anti-solvent precipitation-ultrasound technology and optimised by a 3-factor, 3-level Box- Behnken design. Particle size and zeta potential of the cilnidipine nanoparticles were 60 ± 7.18 nm and -14.5 ± 4.12 mV, respectively. A greater value of pharmacokinetic parameters–maximum plasma concentration and area under curve has indicated better drug absorption in the form of nanoparticles. The value of half-life of cilnidipine nanoparticles (1.2 h) decreased compared to the drug (2.4 h),which concluded that, the increased absorption of cilnidipine nanoparticles. These findings reinforce that the formulation of nanoparticles is a new approach for solubility and bioavailability enhancement of cilnidipine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
